Related Experiment Video
Updated: Sep 11, 2025

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs
Rema Iyer1, Anagha Deshpande1, Aditi Pedgaonkar1
1Cancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Abstract:
Synovial sarcoma (SySa) is an aggressive soft tissue sarcoma with an urgent need to develop targeted therapies. Here, we exploited specific vulnerabilities created by transcriptional rewiring by the fusion protein SS18::SSX, the sole oncogenic driver in SySa. To uncover genes that are selectively essential for the fitness of SySa cells compared to other tumor cell lines, we mined the Cancer-Dependency-Map data. Targeted CRISPR library screening of SySa-selective candidates revealed that the small ubiquitin-like modifier 2 (SUMO2) constituted one of the strongest dependencies both in vitro and in vivo. TAK-981, a clinical-stage small-molecule SUMO2 inhibitor potently suppressed growth and colony-forming ability. Transcriptomic profiling showed that SUMO2 inhibition elicited a profound reversal of the gene expression program orchestrated by SS18::SSX fusion. Further, genetic depletion or SUMO2 inhibition reduced global expression levels and chromatin occupancy of the SS18::SSX fusion protein with a concomitant reduction in histone 2A lysine 119 ubiquitination (H2AK119ub), an epigenetic mark facilitating SySa pathogenesis. Taken together, our study identifies SUMO2 as a novel, selective vulnerability in synovial sarcoma, suggesting new avenues for targeted treatment of soft tissue tumors.
Insights
Researchers identified small ubiquitin-like modifier 2 (SUMO2) as a key dependency in synovial sarcoma (SySa). Inhibiting SUMO2 effectively targets SySa cells, offering a promising new therapeutic strategy for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Synovial sarcoma (SySa) is an aggressive soft tissue cancer driven by the SS18::SSX fusion protein.
- There is a critical need for targeted therapies against SySa.
Purpose of the Study:
- To identify genes selectively essential for SySa cell fitness.
- To explore the therapeutic potential of targeting identified vulnerabilities.
Main Methods:
- Mined Cancer Dependency Map data for SySa-selective genes.
- Performed targeted CRISPR library screening.
- Utilized SUMO2 inhibition with TAK-981.
- Conducted transcriptomic profiling and epigenetic analysis.
Main Results:
- Small ubiquitin-like modifier 2 (SUMO2) was identified as a critical dependency in SySa.
- SUMO2 inhibition potently suppressed SySa cell growth in vitro and in vivo.
- SUMO2 inhibition reversed the SS18::SSX-driven gene expression program.
- Targeting SUMO2 reduced SS18::SSX protein levels and H2AK119ub epigenetic marks.
Conclusions:
- SUMO2 is a novel and selective vulnerability in synovial sarcoma.
- Targeting SUMO2 presents a promising therapeutic strategy for soft tissue tumors.
More Related Videos
08:29SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Induced Pluripotent Stem Cells
Somatic...
Targeted Cancer Therapies
There are several types of targeted therapies against...